698 Stock Overview
A biopharmaceutical company, develops precision T cell therapies to treat solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Achilles Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.98 |
| 52 Week High | US$1.43 |
| 52 Week Low | US$0.59 |
| Beta | 1.34 |
| 11 Month Change | 10.73% |
| 3 Month Change | 58.06% |
| 1 Year Change | 34.25% |
| 33 Year Change | -76.67% |
| 5 Year Change | n/a |
| Change since IPO | -90.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 698 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.2% | -1.1% | 1.1% |
| 1Y | 34.2% | -18.8% | 7.2% |
Return vs Industry: 698 exceeded the German Biotechs industry which returned -18.3% over the past year.
Return vs Market: 698 exceeded the German Market which returned 8.6% over the past year.
Price Volatility
| 698 volatility | |
|---|---|
| 698 Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 698's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 698's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 210 | Iraj Ali | www.achillestx.com |
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.
Achilles Therapeutics plc Fundamentals Summary
| 698 fundamental statistics | |
|---|---|
| Market cap | €41.68m |
| Earnings (TTM) | -€63.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs 698 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 698 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$66.88m |
| Earnings | -US$66.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 698 perform over the long term?
See historical performance and comparison